the aid library

LIST OPTIONS

Filter

2211

Sort by:

Direction:

Download (104)

View PDF (142)

Benin: Rapid Assessment of Sexual and Reproductive Health and HIV Linkages

IPPF, UNFPA, WHO, UNAIDS (2011) C2

This summary highlights the experiences, results and actions from the implementation of the Rapid Assessment Tool for Sexual and The tool – developed by IPPF, UNFPA, WHO, UNAIDS, GNP+, ICW and Young Positives in 2009 – supports national assessments of the bi-directional linkages between sexu... more

Download (818)

View PDF (1415)

Guidelines for Accreditation of private health facilities in Providing SBA Training

Maternal Health Division Ministry of Health and Family Welfare Government of India Maternal Health Division Ministry of Health and Family Welfare Government of India (2009) C1

Reference Manual for Programme Managers on Accreditation Process

Download (139)

View PDF (160)

Sick child age 2 months up to 5 years

Ministry of Health and Family Welfare, Pakistan; WHO; UNICEF (2019) C_WHO

Abridge Course for Physicians. Facilitator guide for modules, Integrated Management of Neonatal and Childhood Illness (IMNCI)

Download (638)

View PDF (4308)

Structural violence: Understanding mother & child health and Ebola in Sierra Leone

Schwienhorst, E.M.; K. Boegel Medical Peace Work (2015) C1

This is one of seven Medical Peace Work courses.

Download (280)

View PDF (452)

Integrated Management of Neonatal and Childhood Illness - Facilitator Guide I

Ministry of Health and Family Welfare, Government of India; WHO; UNICEF (2009) C_WHO

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (87)

View PDF (1242)

Poorly Designed PPE a Global Problem forWomen HealthWorkers

Kuehn, B.M. (2022) C1

Download (224)

View PDF (280)

WHO aircraft disinsection methods and procedures

World Health Organization WHO (2021) C_WHO

Download (2211)

View PDF (3344)

For Proper Disposal Hospital Waste

Jorge Emmanuel and Ruth Stringer Health Care Without Harm (2007)

A Global Inventory of Alternative Medical Waste Treatment Technologies

Download (1214)

View PDF (3138)

Four Steps for the Sound Management of Health-Care Waste in Emergencies

World Health Organization (2000) C_WHO

Download (459)

View PDF (906)

Solution Hydro-Alcoolique - Formulation 1 OMS

Pharma-Ed Pharma-Ed (2015) C2

30.03.2015

Download (388)

View PDF (822)

Verification de la concentration d'Ethanol

Pharm-Ed (2015) C1

La concentration en éthanol est mesurée par une méthode densitométrique à l’aide d’un alcoomètre Gay LUSSAC à l’échelle v/v.

Download (417)

View PDF (1034)

CHECK-LISTE du matériel et produits contenus dans un kit OMS pour la production locale de la solution hydro-alcoolique- FORMULATION I

Pharma-Ed Pharma-Ed (2015) C2

15.08.2015

Download (624)

View PDF (1351)

Guidelines for surveillance of drug resistance in tuberculosis

World Health Organization (2021) C_WHO

6th edition

Download (1291)

View PDF (3198)

WHO/UNICEF Strategic Plan for Polio Outbreak Response in the Middle East

The Polio Global Eradication Initiative WHO (2013)

THE SYRIAN ARAB REPUBLIC, IRAQ, JORDAN, LEBANON, TURKEY, WEST BANK AND GAZA STRIP, EGYPT

Download (1195)

View PDF (3519)

Investigating cause of death during an outbreak of Ebola virus haemorrhagic fever: draft verbal autopsy instrument

World Health Organization (2003)

Download (964)

View PDF (2366)

Basic Hygiene. Standard precautions environmental cleaning

German Red Cross (2015) C2

Download (93)

View PDF (425)

Cutaneous Leishmaniasis: Urgent need to develop more effective and user-friendly point-of-care diagnostic tools

DNDi redeLEISH (2022) CC

Leishmaniasis is a complex vector-borne disease involving in its transmission several species of protozoan parasites called Leishmania, a wide variety of animal reservoirs and phlebotomine sandflies vectors. Cutaneous Leishmaniasis (CL) is the most common form of the disease, and its clinical manife... more

Download (11)

View PDF (11)

Malawi’s Community-based Health System Model: Structure, Strategies, and Learning

Devlin, K.; Pandit-Rajani, T.; Egan, F.K. Advancing Partners & Communities (2017) CC

The Community-based Health System Model Series briefs identify and discuss critical health system inputs and processes that have contributed to the implementation and expansion of community-based service delivery in different countries. Countries were selected for their geographic diversity, type o... more

Download (178)

View PDF (233)

Healthy people, healthy business. Strategies for business to strengthen health system resilience

World Business Council for Sustainable Development (WBCSD) (2022) C2

WBCSD Vision 2050 sets out the goal to achieve the highest attainable standard of health and wellbeing for everyone by 2050, calling for a world in which: people live healthy lives; societies promote and protect health; everyone has access to robust, resilient and sustainable healthcare services; an... more